Tzu-Hsuan Huang Selected Research

Neoplasms (Cancer)

1/2022	Molecular interaction mechanisms of glycol chitosan self-healing hydrogel as a drug delivery system for gemcitabine and doxorubicin.
10/2021	An Engineered IL15 Cytokine Mutein Fused to an Anti-PD1 Improves Intratumoral T-cell Function and Antitumor Immunity.
1/2019	Empowering therapeutic antibodies with IFN-α for cancer immunotherapy.
12/2018	Eradication of Triple-Negative Breast Cancer Cells by Targeting Glycosylated PD-L1.
1/2017	Identification of novel resistance mechanisms to NAMPT inhibition via the de novo NAD+ biosynthesis pathway and NAMPT mutation.
3/2015	HER family kinase domain mutations promote tumor progression and can predict response to treatment in human breast cancer.
1/2014	Activation of Keap1/Nrf2 signaling pathway by nuclear epidermal growth factor receptor in cancer cells.
6/2013	Epidermal growth factor receptor potentiates MCM7-mediated DNA replication through tyrosine phosphorylation of Lyn kinase in human cancers.
9/2010	RNA helicase A is a DNA-binding partner for EGFR-mediated transcriptional activation in the nucleus.
7/2009	Up-regulation of miR-21 by HER2/neu signaling promotes cell invasion.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Tzu-Hsuan Huang Research Topics

Disease

11	Neoplasms (Cancer) 01/2022 - 11/2007
3	Breast Neoplasms (Breast Cancer) 03/2015 - 07/2009
1	Experimental Melanoma 10/2021
1	Alzheimer Disease (Alzheimer's Disease) 01/2021
1	Triple Negative Breast Neoplasms 12/2018
1	Fibrosarcoma 01/2017
1	Carcinoma (Carcinomatosis) 03/2015
1	Lung Neoplasms (Lung Cancer) 03/2015
1	Tuberous Sclerosis 1 02/2010
1	Carcinogenesis 02/2010
1	Neoplasm Metastasis (Metastasis) 07/2009
1	B-Cell Lymphoma (Lymphoma, B Cell) 11/2007

Drug/Important Bio-Agent (IBA)

2	Pharmaceutical PreparationsIBA 01/2022 - 12/2018
2	Proteins (Proteins, Gene)FDA Link 01/2019 - 11/2007
2	Epidermal Growth Factor (EGF)IBA 12/2018 - 09/2010
2	Phosphotransferases (Kinase)IBA 03/2015 - 06/2013
2	ErbB Receptors (EGF Receptor)IBA 01/2014 - 06/2013
1	Gemcitabine FDA Link 01/2022
1	Doxorubicin (Adriamycin)FDA LinkGeneric 01/2022
1	Drug CarriersIBA 01/2022
1	HydrogelsIBA 01/2022
1	Interleukin-15 (Interleukin 15)IBA 10/2021
1	Protein Tyrosine PhosphatasesIBA 01/2021
1	AntigensIBA 01/2019
1	AntibodiesIBA 01/2019
1	Programmed Cell Death 1 ReceptorIBA 12/2018
1	B7-H1 AntigenIBA 12/2018
1	TransferasesIBA 12/2018
1	NAD (NADH)IBA 01/2017
1	N- (6- chlorophenoxyhexyl)- N''- cyano- N''- 4- pyridylguanidine (CHS 828)IBA 01/2017
1	Tyrosine Kinase InhibitorsIBA 03/2015
1	Tyrosine (L-Tyrosine)FDA Link 06/2013
1	Cyclin D1IBA 09/2010
1	TOR Serine-Threonine KinasesIBA 02/2010
1	MicroRNAs (MicroRNA)IBA 07/2009
1	Protein-Tyrosine Kinases (Tyrosine Kinase)IBA 07/2009
1	Cell Surface ReceptorsIBA 07/2009
1	Tumor Suppressor Proteins (Proteins, Tumor Suppressor)IBA 07/2009
1	Immunoglobulin G (IgG)IBA 11/2007

Therapy/Procedure

2	Immunotherapy 10/2021 - 01/2019
1	Therapeutics 03/2015
1	Drug Therapy (Chemotherapy) 01/2014